An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics (MESSAGE)

Viatris

Status: Completed

Conditions: Schizophrenia; Metabolic Syndrome X

Treatments: Other: No intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT00448630

A1281160

Details and patient eligibility

About

The purpose of the study is to find and follow-up the metabolic syndrome parameters on patients administering atypical antipsychotics.

Full description

Sampling Method Details: Group of patients using the same atypical anti-psychotic.

Enrollment: 328 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female and male patients diagnosed as schizophrenia by the Diagnostic and Statistical Manual of Mental Disorders.
• Age between 18-45 years
• Patients who started atypical antipsychotic drug treatment or patients who switched from the previous conventional or atypical antipsychotic treatment to another atypical antipsychotic drug treatment by the decision of their physicians.

Exclusion criteria

• Patients who are pregnant or considering pregnancy.

Trial design

328 participants in 1 patient group

Atypical Antispychotics (or second generation antipsychotics)

Description:

Patients with schizophrenia who are currently receiving or are going to start a new treatment with atypical antipsychotics, ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, amisulpride.

Treatment:

Other: No intervention